Pfizer-biontech covid-19 vaccine demonstrates strong immune response, high efficacy and favorable safety in children 6 months to under 5 years of age following third dose

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced topline safety, immunogenicity and vaccine efficacy data from a phase 2/3 trial evaluating a third 3-Μg dose of the pfizer-biontech covid-19 vaccine in children 6 months to under 5 years of age. following a third dose in this age group, the vaccine was found to elicit a strong immune response, with a favorable safety profile similar to placebo. vaccine efficacy, a secondary endpoin
BNTX Ratings Summary
BNTX Quant Ranking